Verubecestat
Clinical data | |
---|---|
ATC code | None |
Legal status | |
Legal status |
|
Identifiers | |
Synonyms | MK-8931 |
CAS Number | 1286770-55-5 |
PubChem (CID) | 51352361 |
ChemSpider | 31399364 |
UNII | J1I0P6WT7T |
KEGG | D10739 |
Chemical and physical data | |
Formula | C17H17F2N5O3S |
Molar mass | 409.41 g·mol−1 |
3D model (Jmol) | Interactive image |
| |
|
Verubecestat (MK-8931) is an experimental drug for the treatment of Alzheimer's disease.[1] It is an inhibitor of beta-secretase 1 (BACE1).[2][3]
References
- ↑ Simon Makin (November 2, 2016). "New Alzheimer's Drug Clears Milestone in Human Clinical Trial". Scientific American.
- ↑ Forman, Mark; Kleijn, Huub-Jan; Dockendorf, Marissa; Palcza, John; Tseng, Jack; Canales, Christina; Egan, Michael; Kennedy, Matthew; Laterza, Omar; Ma, Lei; Scott, Jack; Tanen, Michael; Apter, Jeffrey; Backonja, Miroslav; Ereshefsky, Larry; Gevorkyan, Hakop; Jhee, Stanford; Rynders, Rebecca; Zari, Arian; Bryan, Ellie; Wagner, John; Troyer, Matthew; Stone, Julie (2013). "The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease". Alzheimer's & Dementia. 9 (4): P139. doi:10.1016/j.jalz.2013.04.083.
- ↑ Yan, Riqiang; Vassar, Robert (2014). "Targeting the β secretase BACE1 for Alzheimer's disease therapy". The Lancet Neurology. 13 (3): 319. doi:10.1016/S1474-4422(13)70276-X. PMID 24556009.
This article is issued from Wikipedia - version of the 11/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.